Starting July 1, 2023, Australia will allow the use of psilocybin and 3,4-Methylenedioxymethamphetamine (MDMA) for therapeutic use in a medical setting to treat mental health conditions.
On February 3, 2023 the Australian Therapeutic Goods Administration (TGA) released their decision relating to psilocybin and 3,4-Methylenedioxymethamphetamine (MDMA), following applications made to the TGA, public consultation, an expert panel report, and advice from the Advisory Committee on Medicines Scheduling (1). The TGA will allow the use of psilocybin and MDMA for therapeutic use in a medical setting, specifically to treat mental health conditions. A press release outlined who can prescribe the drugs and acknowledged the current lack of options for mental illness treatment (1). For therapeutic purposes, these substances are placed into Schedule 8 (Controlled Drugs) but remain in Schedule 9 (Prohibited Substances) for unauthorized use.
“From 1 July this year, medicines containing the psychedelic substances psilocybin and MDMA (3,4-methylenedioxy-methamphetamine) can be prescribed by specifically authorised psychiatrists for the treatment of certain mental health conditions,” began the press release (1). “The decision acknowledges the current lack of options for patients with specific treatment-resistant mental illnesses. It means that psilocybin and MDMA can be used therapeutically in a controlled medical setting. However, patients may be vulnerable during psychedelic-assisted psychotherapy, requiring controls to protect these patients.”
According to the Multidisciplinary Association for Psychedelic Studies (MAPS), Australia will be the fourth country to legalize psychedelic substances for therapeutic use for mental health, after Israel, the United States, and Canada (2). In the US, recent activity around psychedelics for therapeutic use include petitions to the Drug Enforcement Agency (DEA) to place psilocybin in a lower drug schedule, legislation to legalize possession of certain psychedelics in California, and requests to theNational Institutes on Health (NIH) and Food and Drug Administration (FDA) for updates on research into the therapeutic potential of psychedelics (3).
References
Collaboration, Gender Diversity, and Progress: Julie Kowalski on Advancing Cannabis Science
December 10th 2024In this interview with Cannabis Science and Technology, Julie Kowalski, an experienced analytical chemist, discusses her path into the cannabis industry, starting with early work in gas chromatography. Kowalski reflects on her perspectives as a female scientist, highlighting biases she’s experienced and the benefits of gender inclusivity in the cannabis space. Greater unity and professionalism could benefit the industry as a whole, she explains. She also encourages collaboration and more women in leadership positions in order to build a stronger scientific community, and also urges women to advocate for themselves, noting that women in cannabis face unique obstacles but often demonstrate consensus-building strategies and solutions.
Ep 24, Part I: Data Transparency in Cannabis Testing with Yasha Khan
November 21st 2024Evan Friedmann interviews Yasha Khan, co-founder of MCR Labs, about his journey into the cannabis industry and his efforts to promote transparency and integrity in laboratory practices. Yasha discusses the origins of MCR Labs, which began in Massachusetts to meet the needs of the soon-to-be legal medical cannabis market. He explains the challenges faced, including result manipulation by labs and the impact on public health. Yasha's Freedom of Information Act (FOIA) project aimed to gather testing data from 37 states, revealed significant discrepancies in potency and mold results. Despite some states' reluctance to share data, Yasha has made much of this data public, leading to collaborative research and publications on various aspects of cannabis testing.
Gender Diversity and Innovation in the Cannabis Space: Insights from Tess Eidem, PhD
December 9th 2024Cannabis Science and Technology sat down with Tess Eidem, PhD, PCQI, member of Saturn Scientific, LLC, to discuss her journey from antibiotic research to cannabis microbiology and her observations throughout her career. Dr. Eidem highlights challenges women face in this male-dominated industry, including limited representation in leadership roles and frequent experiences of bias and discrimination. She emphasizes the importance of gender diversity in fostering innovation, improving product safety, and addressing women’s health needs in cannabis applications. Her advice to women scientists is to build strong professional relationships and carefully evaluate work environments to advance their careers in this evolving and often challenging space.
Ep 23, Part III: Accreditation in the Cannabis Industry with Susan Audino
October 24th 2024In Part III of this episode, host Evan Friedmann is joined by Susan Audino, PhD, founder of S.A. Audino & Associates, LLC, and co-founder of Saturn Scientific, LLC, to examine the complexities of sampling in the cannabis industry, emphasizing the need for proper sampling plans, and methods.